FrancophonIA/ELRC3.0 huggingface dataset:
English: if you are currently taking any of the following medicines: astemizole or terfenadine (commonly used to treat allergy symptoms - these medicines may be available without prescription); amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, quinidine (used to correct irregular heartbeats); dihydroergotamine, ergotamine (used to treat migraine headache); ergonovine, methylergonovine (used to stop excessive bleeding that may occur following childbirth or an abortion); clorazepate, diazepam, estazolam, flurazepam, triazolam or oral (taken by mouth) midazolam (used to help you sleep and/or relieve anxiety); clozapine, pimozide, (used to treat abnormal thoughts or feelings); quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder); lurasidone (used to treat depression); ranolazine (used to treat chronic chest pain [angina]); pethidine, piroxicam, propoxyphene (used to relieve pain); cisapride (used to relieve certain stomach problems);
Slovenian: če trenutno jemljete katero od naslednjih zdravil: astemizol ali terfenadin (pogosto se uporabljata za zdravljenje simptomov alergije - ti zdravili utegneta biti na voljo brez recepta), amiodaron, bepiridil, dronedaron, enkainid, flekainid, propafenon, kinidin (uporabljajo se za odpravljanje nerednega bitja srca), dihidroergotamin, ergotamin (uporabljata se za zdravljenje migrenskega glavobola), ergonovin, metilergonovin (uporabljata se za ustavljanje čezmerne krvavitve, ki se lahko pojavi po porodu ali splavu), klorazepat, diazepam, estazolam, flurazepam, triazolam ali peroralni (zaužiti) midazolam (uporabljajo se proti nespečnosti in/ali za odpravljanje tesnobnosti), klozapin, pimozid (uporabljata se za zdravljenje nenormalnih misli in čustev), kvetiapin (uporablja se za zdravljenje shizofrenije, bipolarnih motenj in velike depresivne motnje), lurasidon (uporablja se za zdravljenje depresije), ranolazin (uporablja se za zdravljenje kronične bolečine v prsnem košu [angina pektoris]),petidin, piroksikam, propoksifen (uporabljajo se za lajšanje bolečin), cisaprid (uporablja se za lajšanje določenih težav z želodcem),
English: McDermott Laboratories Limited trading as Gerard Laboratories trading as Mylan Dublin, Unit 35/36 Baldoyle Industrial Estate,
Slovenian: Generics [UK] Limited, Station Close, Potters Bar, Hertfordshire, EN6 1TL, Združeno kraljestvo McDermott Laboratories Limited trading as Gerard Laboratories trading as Mylan Dublin, Unit 35/36 Baldoyle Industrial Estate,
English: Pharmacokinetic data indicate that no dose adjustment is necessary in patients with mild to moderate hepatic impairment (see section 5.2).
Slovenian: Farmakokinetični podatki kažejo, da odmerka pri bolnikih z blago do zmerno okvaro jeter po vsem sodeč ni treba prilagajati (glejte poglavje 5.2).
English: LIST OF EXCIPIENTS High in sodium - see leaflet for further information.
Slovenian: SEZNAM POMOŽNIH SNOVI Velika vsebnost natrija - pred uporabo preberite priloženo navodilo.
English: Increased glucose, increased magnesium, increased alkaline phosphatase
Slovenian: Preiskave pogosti zvišanje amilazeznižanje prostega in celotnega tiroksina občasni zvišanje glukoze, zvišanje magnezija, zvišanje alkalne fosfataze
English: However, due to ritonavir's metabolic inhibitory properties its use as a pharmacokinetic enhancer of other protease inhibitors is the prevalent use of ritonavir in clinical practice (see section 4.2).
Slovenian: Toda ker ritonavir zavira presnovo, se v klinični praksi pretežno uporablja kot farmakokinetični stopnjevalec drugih zaviralcev proteaz (glejte poglavje 4.2).
English: Repeated dose toxicity studies in animals identified major target organs as the liver, retina, thyroid gland and kidney.
Slovenian: V študijah toksičnosti pri ponavljajočih se odmerkih na živalih so kot glavne ciljne organe ugotovili jetra, mrežnico, ščitnico in ledvice.
English: Caution must also be exercised and reduced doses should be considered if ritonavir is used concurrently with atorvastatin, which is metabolised to a lesser extent by CYP3A.
Slovenian: Previdnost je potrebna tudi pri hkratni uporabi ritonavirja z atorvastatinom, ki se v manjši meri presnavlja s CYP3A; v poštev pride zmanjšanje odmerkov.
English: Increased plasma concentrations of cisapride.
Slovenian: Zvišana koncentracija cisaprida v plazmi.
English: Ritonavir should not be given to patients with decompensated liver disease (see section 4.2).
Slovenian: Ritonavirja ne smejo dobiti bolniki z dekompenzirano boleznijo jeter (glejte poglavje 4.2).
English: The following medicines are contraindicated when used with ritonavir and unless otherwise noted, the contraindication is based on the potential for ritonavir to inhibit metabolism of the co-administered medicinal product, resulting in increased exposure to the co-administered medicinal product and risk of clinically significant adverse effects.
Slovenian: Če ni navedeno drugače, temelji kontraindikacija na možnosti, da ritonavir zavre presnovo sočasno uporabljenega zdravila, kar povzroči večjo izpostavljenost sočasno uporabljenemu zdravilu in tveganje za klinično pomembne neželene učinke.
English: Tipranavir must be given with low dose ritonavir to ensure its therapeutic effect.
Slovenian: Za zagotovitev terapevtskega učinka je treba tipranavir dajati z nizkoodmernim ritonavirjem.
English: Endothelin antagonists Bosentan
Slovenian: Antagonisti endotelinskih receptorjev
English: C-labelled ritonavir in rats showed the liver, adrenals, pancreas, kidneys and thyroid to have the highest concentrations of ritonavir.
Slovenian: C-označenim ritonavirjem pri podganah so pokazale najvišje koncentracije ritonavirja v jetrih, nadledvičnih žlezah, trebušni slinavki, ledvicah in ščitnici.
English: The concomitant use of ritonavir is not recommended due to potential increase in riociguat exposure (see section 4.5).
Slovenian: Sočasna uporaba ritonavirja ni priporočljiva zaradi možnosti povečanja izpostavljenosti riociguatu (see section 4.5).
English: The degree of enhancement is related to the metabolic pathway of the co-administered protease inhibitor and the impact of the co-administered protease inhibitor on the metabolism of ritonavir.
Slovenian: Izrazitost stopnjevanja je povezana s presnovno potjo sočasno uporabljenega zaviralca proteaz in od vpliva tega zaviralca na presnovo ritonavirja.
English: The other tablet ingredients are: copovidone, sorbitan laurate, colloidal anhydrous silica, sodium chloride, sodium stearyl fumarate see section 2 ‘Ritonavir Mylan contains sodium'.
Slovenian: Pomožne snovi v tableti so: kopovidon, sorbitan lavrat, koloidni brezvodni silicijev dioksid, natrijev klorid, natrijev stearilfumarat (gletje poglavje 2 ''Zdravilo Ritonavir Mylan vsebuje natrij'').
English: Darunavir 600 mg twice daily with ritonavir 100 mg twice daily in antiretroviral treatment.
Slovenian: Darunavir 600 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan pri bolnikih, ki so bili predhodno zdravljeni z antiretrovirusno terapijo (ART).
English: 3 Based on cross-study comparison to 800 mg indinavir three times daily alone.
Slovenian: Na podlagi medštudijske primerjave z 800 mg samega indinavirja trikrat na dan. 4.
English: 4 Based on cross-study comparison to 600 mg saquinavir three times daily alone.
Slovenian: Na podlagi medštudijske primerjave s 600 mg samega sakvinavirja trikrat na dan.
English: 0.4 single oral dose
Slovenian: 0,4, posamičen peroralen odmerek
English: Doses of ritonavir higher than 100 mg twice daily should not be used.
Slovenian: Odmerkov ritonavirja, večjih od 100 mg dvakrat na dan, ne smete uporabljati.
English: More frequent electrocardiogram monitoring and monitoring of transaminases is recommended (see section 4.5 and refer to the bedaquiline Summary of Product Characteristics).
Slovenian: Priporočeno je pogostejše spremljanje z elektrokardiogrami in spremljanje koncentracij transaminaz (glejte poglavje 4.5 in poglejte v povzetek glavnih značilnosti zdravila za bedakilin).
English: Concomitant administration of ritonavir and quetiapine is contraindicated as it may increase quetiapine-related toxicity (see section 4.3).
Slovenian: Sočasna uporaba ritonavirja in kvetiapina je kontraindicirana, ker lahko poveča toksičnost, povezano s kvetiapinom (glejte poglavje 4.3).
English: The following HIV-1 protease inhibitors have been approved for use with ritonavir as a pharmacokinetic enhancer at the noted doses.
Slovenian: Za uporabo z ritonavirjem kot farmakokinetičnim stopnjevalcem so odobreni naslednji zaviralci proteaz HIV-1 v navedenih odmerkih.
English: Thereby, increasing the risk of arrhythmias or other serious adverse effects from these agents.
Slovenian: S tem se poveča tveganje za aritmije ali druge resne neželene učinke teh zdravil.
English: Ritonavir inhibits CYP3A4 and as a result a pronounced increase in the plasma concentrations of salmeterol is expected.
Slovenian: Ritonavir zavira CYP3A4 in pričakovati je treba izrazito zvišanje koncentracije salmeterola v plazmi.
English: Medicinal products that affect ritonavir levels
Slovenian: Zdravila, ki vplivajo na koncentracijo ritonavirja
English: 1 Based on cross-study comparison to 400 mg atazanavir once daily alone.
Slovenian: Na podlagi medštudijske primerjave s 400 mg samega atazanavirja enkrat na dan. 2.
English: 200 q12 h, 2 days
Slovenian: 200 na 12 ur, 2 dni
English: • severe or life threatening skin reaction including blisters (Stevens Johnson syndrome, toxic epidermal necrolysis)
Slovenian: Redki: pojavijo se lahko pri 1 od 1000 bolnikov - hude ali smrtno nevarne kožne reakcije, vključno z mehurji (Stevens-Johnsonov sindrom, toksična epidermalna nekroliza)
English: Patients with impaired renal function
Slovenian: Bolniki z okvarjenim delovanjem ledvic
English: While rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with ritonavir co-administration.
Slovenian: Izločanje rosuvastatina ni odvisno od CYP3A, vendar je med sočasno uporabo z ritonavirjem opisano povečanje izpostavljenosti rosuvastatinu.
English: Initiate treatment with saquinavir 500 mg twice daily with ritonavir 100 mg twice daily for the first 7 days, then saquinavir 1,000 mg twice daily with ritonavir 100 mg twice daily in ART-naïve patients.
Slovenian: Pri bolnikih, ki še niso bili zdravljeni z antiretrovirusno terapijo (ART), začnite z zdravljenjem s sakvinavirjem 500 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan prvih 7 dni, nato nadaljujte s sakvinavirjem 1000 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan.
English: Concomitant use of avanafil or vardenafil with ritonavir is contraindicated (see section 4.3).
Slovenian: Sočasna uporaba avanafila ali vardenafila z ritonavirjem je kontraindicirana (glejte poglavje 4.3).
English: 5, single dose
Slovenian: 5, posamičen odmerek
English: Ritonavir adversely interacts with oral contraceptives (OCs).
Slovenian: Ritonavir ima neželeno medsebojno delovanje s peroralnimi kontraceptivi.
English: Colchicine (for gout) as ritonavir may raise the blood levels of this medicine.
Slovenian: Kolhicin (za zdravljenje protina), ker ritonavir lahko poveča koncentracijo tega zdravila v krvi.
English: Please also review the Summary of Product Characteristics for the particular boosted PI.
Slovenian: Glejte tudi povzetek glavnih značilnosti za posamezni spodbujevani zaviralec proteaz.
English: The concomitant use of ritonavir is not recommended due to potential increase in vorapaxar exposure (see section 4.5).
Slovenian: Sočasna uporaba ritonavirja ni priporočljiva zaradi možnosti povečane izpostavljenosti vorapaksarju (glejte poglavje 4.5).
English: PDE5 inhibitor
Slovenian: Zaviralec PDE5
English: 1, single dose
Slovenian: 1, posamičen odmerek
English: Ritonavir must not be given to patients with severe hepatic impairment (see section 4.3).
Slovenian: Zdravila ritonavir ne smejo dobiti bolniki s hudo okvaro jeter (glejte poglavje 4.3).
English: The renal clearance of ritonavir is negligible therefore; a decrease in the total body clearance is not expected in patients with renal impairment.
Slovenian: Ledvični očistek ritonavirja je zanemarljiv; zato pri bolnikih z okvaro ledvic ni pričakovati zmanjšanja celotnega telesnega očistka.
English: 300 q6 h
Slovenian: 300 na 6 ur
English: Common: may affect up to 1 in 10 people
Slovenian: Pogosti: pojavijo se lahko pri 1 od 10 bolnikov
English: Ritonavir effects on non-antiretroviral co-administered medicinal products
Slovenian: Učinki ritonavirja na sočasno uporabljena neretrovirusna zdravila
English: 200 q8 h
Slovenian: 200 na 8 ur
English: Serum concentrations may be increased due to CYP3A and P-gp inhibition by ritonavir.
Slovenian: Serumske koncentracije se lahko povečajo zaradi CYP3A in P-gp zavrtja z ritonavirjem.
English: Patients with impaired liver function
Slovenian: Bolniki z okvarjenim delovanjem jeter
English: Common Rare
Slovenian: pogosti akne redko
English: Uncommon Rare oedema and peripheral oedema, dehydration (usually associated with gastrointestinal symptoms) Diabetes mellitus Hyperglycaemia
Slovenian: Presnovne in prehranske motnje pogosti hiperholesterolemija, hipertrigliceridemija, protin, edem in periferni edem, dehidracija (ponavadi povezana z gastrointestinalnimi simptomi)
English: How to take Ritonavir Mylan
Slovenian: Kako jemati zdravilo Ritonavir Mylan
English: The Day 3 ritonavir exposure was approximately 1.5 fold higher than that observed with the 600 mg twice daily dose at steady state.
Slovenian: Med tema režimoma uporabe je bila izpostavljenost 3. dan 1,5-krat večja kot med uporabo 600 mg odmerka ritonavirja dvakrat na dan v stanju dinamičnega ravnovesja.
English: 500 q12 h,
Slovenian: 500 na 12 ur,
English: Ritonavir should not be given as a pharmacokinetic enhancer to patients with decompensated liver disease, (see section 4.3).
Slovenian: Ritonavirja kot farmakokinetičnega stopnjevalca ne smejo dobiti bolniki z dekompenzirano boleznijo jeter (glejte poglavje 4.3).
English: 300 q24 h
Slovenian: 300 na 24 ur
English: 2 Based on cross-study comparison to 1,200 mg amprenavir twice daily alone.
Slovenian: Na podlagi medštudijske primerjave s 1200 mg samega amprenavirja dvakrat na dan. 3.
English: Ritonavir dosed as an antiretroviral agent
Slovenian: Ritonavir, odmerjan kot protiretrovirusno zdravilo
English: Thereby, increasing the risk of serious arrhythmias from this agent.
Slovenian: S tem se poveča tveganje za resne aritmije, povzročene s tem zdravilom.
English: Important information regarding medicinal product interactions when ritonavir is used as a pharmacokinetic enhancer is also contained in the Summary of Product Characteristics of the co-administered protease inhibitor.
Slovenian: Pomembne informacije o medsebojnem delovanju zdravil med uporabo ritonavirja kot farmakokinetičnega stopnjevalca vsebuje tudi povzetek glavnih značilnosti sočasno uporabljenega zaviralca proteaz.
English: 600 q24 h
Slovenian: 600 na 24 ur
English: 50 μg, single dose
Slovenian: 50 µg, posamičen odmerek
English: Renal failure, renal impairment, elevated creatinine, hypophosphataemia and proximal tubulopathy (including Fanconi syndrome) have been reported with the use of tenofovir disoproxil fumarate (DF) in clinical practice (see section 4.8).
Slovenian: V klinični praksi so pri sočasni uporabi dizoproksiltenofovirijevega fumarata (DF) poročali o pojavu odpovedi ledvic, okvare ledvic, povečane koncentracije kreatinina, hipofosfatemije in proksimalne tubulopatije (vključno s Fanconijevim sindromom) (glejte poglavje 4.8).
English: In intent to treat analyses, 50% and 57% of patients in the 350 and 450 mg/m2 dose groups, respectively, achieved reduction in plasma HIV-1 RNA to ≤ 400 copies/ml at Week 48.
Slovenian: V analizi vključenih bolnikov je zmanjšanje HIV-1 RNA v plazmi na ≤ 400 izvodov/ml do 48. tedna doseglo 50 % bolnikov v skupini s 350 mg/m2 in 57 %
English: Co-administration of atazanavir with ritonavir at doses greater than 100 mg once daily has not been clinically evaluated.
Slovenian: Sočasna uporaba atazanavirja z ritonavirjem v odmerkih, večjih kot 100 mg enkrat na dan, ni klinično ocenjena.
English: Paediatric population (2 years of age and above) The recommended dosage of ritonavir in children is 350 mg/m2 by mouth twice daily and should not exceed 600 mg twice daily.
Slovenian: Pediatrična populacija (od 2. leta dalje) Priporočeno odmerjanje ritonavirja pri otrocih je 350 mg/m peroralno dvakrat na dan in ne sme preseči 600 mg dvakrat na dan. Ritonavir je treba na začetku uporabljati v odmerku 250 mg/m in ga v presledkih od 2 do 3 dni zvečevati po 50 mg/m dvakrat na dan.
English: Maximum PR interval was 252 msec and no second or third degree heart block was observed (see section 4.4).
Slovenian: Povprečna sprememba dolžine intervala PR v primerjavi z izhodiščem je bila med 12-urnim obdobjem po odmerku od 11,0 msec do 24,0 msec. Najdaljši interval PR je bil 252 msec, primerov srčnega bloka druge ali tretje stopnje pa ni bilo (glejte poglavje 4.4).
English: Morphine levels may be decreased due to induction of glucuronidation by co-administered ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Slovenian: Koncentracija morfina se lahko zviša zaradi glukuronidacije, ki jo inducira sočasna uporaba ritonavirja, odmerjanega kot protivirusno zdravilo ali farmakokinetični stopnjevalec.
English: Ritonavir, co-administration is likely to result in increased plasma concentrations of amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and quinidine and is therefore contraindicated (see section 4.3).
Slovenian: Sočasna uporaba ritonavirja ponavadi zviša koncentracijo amiodarona, bepridila, dronedarona, enkainida, flekainida, propafenona in kinidina v plazmi in je zato kontraindicirana (glejte poglavje 4.3).
English: Increased plasma concentrations of lurasidone which may increase the potential for serious and/or life-threatening reactions (see section 4.5).
Slovenian: Večja koncentracija lurasidona v plazmi, ki lahko poveča možnost za resne in/ali življenje ogrožajoče reakcije (glejte poglavje 4.5).
English: Ritonavir pharmacokinetic parameters were not statistically significantly associated with body weight or lean body mass. Ritonavir plasma exposures in patients 50 - 70 years of age when dosed 100 mg in combination with lopinavir or at higher doses in the absence of other protease inhibitors is similar to that observed in younger adults.
Slovenian: Če je ritonavir uporabljen v odmerku 100 mg v kombinaciji z lopinavirjem ali če je uporabljen v večjih odmerkih brez drugih zaviralcev proteaz, je izpostavljenost ritonavirju v plazmi pri bolnikih v starosti od 50 do 70 let podobna kot pri mlajših odraslih osebah.
English: For specific dosing information in patients with renal impairment, refer to the Summary of Product Characteristics (SPC) of the co-administered protease inhibitor.
Slovenian: Za specifične informacije o odmerjanju pri bolnikih z okvaro ledvic glejte povzetek glavnih značilnosti (SPC) sočasno uporabljenega zaviralca proteaz.
English: Caution should be exercised in administering afatinib with ritonavir (refer to the afatinib SmPC).
Slovenian: Pri uporabi afatiniba z ritonavirjem je potrebna previdnost (glejte povzetek glavnih značilnosti zdravila za afatinib).
English: Ritonavir medicinal product level decreased Herbal preparation
Slovenian: Znižanje koncentracije ritonavirja Zdravila rastlinskega izvora
English: Pharmacotherapeutic group: antivirals for systemic use, protease inhibitors ATC code: J05AE03.
Slovenian: Oznaka ATC: J05AE03.
English: Gradually increasing the dose of ritonavir when initiating therapy may help to improve tolerance.
Slovenian: Prenašanje zdravila je mogoče izboljšati s postopnim zvečevanjem odmerka ritonavirja na začetku zdravljenja.
English: 500 q12 h ↑ 145% ↑ 22% The AUC and Cmax of the 2-hydroxy metabolite were decreased 15 and 67%, respectively.
Slovenian: AUC 2-hidroksi presnovka se je zmanjšala za 15 %, njegova Cmax pa za 67 %.
English: ↔ ↑ 4 fold
Slovenian: ↑ 4-krat
English: The Summary of Product Characteristics of other protease inhibitors or official continuous updates should be consulted for specific information regarding protease mutations associated with reduced response to these agents.
Slovenian: Za specifične informacije o mutacijah proteaz, povezanih z manjšim odzivom na ta zdravila, glejte povzetke glavnih značilnosti drugih zaviralcev proteaz ali stalne uradne posodobitve.
English: Increased plasma concentrations of amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, quinidine.
Slovenian: Zvišana koncentracija amiodarona, bepridila, dronedarona, enkainida, flekainida, propafenona, kinidina v plazmi.
English: 400 q12 h Indinavir3 Ritonavir
Slovenian: Indinavir3↔ ↑ 4-krat Ritonavir↔ ↔
English: Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infected patients (adults and children of 2 years of age and older).
Slovenian: Ritonavir je indiciran za zdravljenje bolnikov (odraslih in otrok od 2. leta dalje), okuženih s HIV-1, v kombinaciji z drugimi protiretrovirusnimi zdravili.
English: Serum levels of ritonavir may be affected by select co-administered medicinal products (e.g. delavirdine, efavirenz, phenytoin and rifampicin).
Slovenian: Določena sočasno uporabljana zdravila (npr. delavirdin, efavirenz, fenitoin in rifampicin) lahko vplivajo na koncentracijo ritonavirja v serumu.
English: Ritonavir dosing regimen
Slovenian: Odmerna shema ritonavirja
English: When used with ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent, the lowest possible doses of atorvastatin or rosuvastatin should be administered.
Slovenian: Če sta atorvastatin ali rosuvastatin uporabljena hkrati z ritonavirjem kot farmakokinetičnim stopnjevalcem ali protiretrovirusnim zdravilom, je treba uporabiti najmanjše možne odmerke atorvastatina ali rosuvastatina.
English: Medicinal Product Assessed
Slovenian: Ocenjena zdravila
English: NAME OF THE MEDICINAL PRODUCT Ritonavir Mylan 100 mg film-coated tablets
Slovenian: IME ZDRAVILA Ritonavir Mylan 100 mg filmsko obložene tablete
English: When ritonavir is used as a pharmacokinetic enhancer with other protease inhibitors the Summary of Product Characteristics for the particular protease inhibitor must be consulted.
Slovenian: Če je ritonavir uporabljen kot farmakokinetični stopnjevalec z drugimi zaviralci proteaz, je treba upoštevati tudi povzetek glavnih značilnosti zadevnega zaviralca proteaz.
English: HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Slovenian: Pri zaviralcih reduktaze HMG-CoA, ki so zelo odvisni od presnove s CYP3A (npr. lovastatin in simvastatin), je treba med sočasno uporabo z ritonavirjem, odmerjanem kot protiretrovirusno zdravilo ali farmakokinetični stopnjevalec, pričakovati izrazito zvišanje njihove koncentracije v plazmi.
English: In a healthy volunteer drug interaction study of delamanid 100 mg twice daily and lopinavir/ritonavir 400/100 mg twice daily for 14 days, the
Slovenian: V študiji medsebojnega delovanja pri zdravih prostovoljcih, ki so 14 dni prejemali 100 mg delamanida dvakrat na dan in lopinavir/ritonavir 400/100 mg dvakrat na dan je bila izpostavljenost presnovka delamanida DM-6705 povečana za 30 %.
English: Also, the side effects of ritonavir when used with other antiretroviral medicines are dependent on the other medicines.
Slovenian: Če ritonavir uporabljate skupaj z drugimi protiretrovirusnimi zdravili, so njegovi neželeni učinki odvisni tudi od teh drugih zdravil.
English: Co-administration of fosamprenavir with ritonavir in doses greater than 100 mg twice daily has not been clinically evaluated.
Slovenian: Sočasna uporaba fosamprenavirja z ritonavirjem v odmerkih, večjih kot 100 mg dvakrat na dan, ni klinično ocenjena.
English: Ritonavir dosed as a pharmacokinetic enhancer
Slovenian: Ritonavir, odmerjan kot farmakokinetični stopnjevalec